ACIP更新甲肝疫苗暴露后及国际旅行前预防建议
ACIP甲肝疫苗工作组系统复习了>40岁人群暴露后接种疫苗、婴儿疫苗效力与安全性及旅行前保护的证据,于2018年2月21日更新建议:≥12月龄者暴露后均应接种甲肝疫苗,>40岁者可加用免疫球蛋白;6–11月龄旅行婴儿应接种疫苗但该剂次不计入常规2剂程序。
要点
- ≥12月龄者暴露后预防应接种甲肝疫苗,>40岁者可依风险评估加用免疫球蛋白。
- 6–11月龄旅行婴儿推荐接种甲肝疫苗,该剂次不计入常规2剂系列。
- 免疫球蛋白剂量更新为0.1 mL/kg,疫苗暴露后预防较免疫球蛋白具主动免疫等优势。
核心结论
- 暴露后2周内使用甲肝疫苗或免疫球蛋白可有效预防甲肝病毒感染。
- ACIP 2018年2月21日建议更新并取代既往甲肝疫苗暴露后及国际旅行建议。
研究设计与样本
- ACIP甲肝疫苗工作组对>40岁人群暴露后接种疫苗证据进行系统复习,并审查婴儿疫苗效力与安全性及旅行前保护获益。
主要发现
- 暴露后2周内给予甲肝疫苗或免疫球蛋白可有效预防甲肝病毒感染。
- 甲肝疫苗或免疫球蛋白可为前往高或中等甲肝地方性流行国家的未接种旅行者提供暴露前保护。
关键数值与推荐
- ≥12月龄所有人群暴露后预防应接种甲肝疫苗。
- >40岁人群除甲肝疫苗外,可根据提供者风险评估给予免疫球蛋白。
- 6–11月龄旅行婴儿应接种甲肝疫苗,该剂次不计入常规2剂系列。
- 免疫球蛋白剂量更新为0.1 mL/kg(适用时)。
临床怎么用
- 暴露后2周内评估并给予≥12月龄者甲肝疫苗,>40岁者结合风险评估加用免疫球蛋白。
- 6–11月龄旅行婴儿接种甲肝疫苗时,该剂次不纳入常规2剂程序。
- 免疫球蛋白按0.1 mL/kg使用(适用时)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Postexposure prophylaxis (PEP) with hepatitis A (HepA) vaccine or immune globulin (IG) effectively prevents infection with hepatitis A virus (HAV) when administered within 2 weeks of exposure. Preexposure prophylaxis against HAV infection through the administration of HepA vaccine or IG provides protection for unvaccinated persons traveling to or working in countries that have high or intermediate HAV endemicity. The Advisory Committee on Immunization Practices (ACIP) Hepatitis Vaccines Work Group conducted a systematic review of the evidence for administering vaccine for PEP to persons aged >40 years and reviewed the HepA vaccine efficacy and safety in infants and the benefits of protection against HAV before international travel. The February 21, 2018, ACIP recommendations update and supersede previous ACIP recommendations for HepA vaccine for PEP and for international travel. Current recommendations include that HepA vaccine should be administered to all persons aged ≥12 months for PEP. In addition to HepA vaccine, IG may be administered to persons aged >40 years depending on the provider's risk assessment. ACIP also recommended that HepA vaccine be administered to infants aged 6-11 months traveling outside the United States when protection against HAV is recommended. The travel-related dose for infants aged 6-11 months should not be counted toward the routine 2-dose series. The dosage of IG has been updated where applicable (0.1 mL/kg). HepA vaccine for PEP provides advantages over IG, including induction of active immunity, longer duration of protection, ease of administration, and greater acceptability and availability.
引用
- Nelson NP, Link-Gelles R, Hofmeister MG, et al. Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel. MMWR Morb Mortal Wkly Rep. 2018. PMID: 30383742. doi:10.15585/mmwr.mm6743a5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。